Infectious Diseases Research

Below are current clinical trials.

269 studies in Infectious Diseases Research
(all studies, either open or closed).

Filter this list of studies by location, status and more.

1. A Study to Evaluate the Pandemic Response Optimizing Technology and Ethics for Coronavirus Teams Implementing Novel Genetics

   Rochester, Minn.

   The purpose of this study is to explore lay understandings toward participating in and perceptions of consent to biospecimen research and valuation of genetics in SARS-COV-2 infection, testing, immunity, and vaccine development, to explore professional attitudes toward and perception of barriers and facilitators for implementating genetic technology to facilitate understanding of SARS-COV-2 infection and immunity, improvement and scale-up of testing, and vaccine development, and to identify ethical, social, and inter-professional aspects of microbial genetic technology implementation in population health surveillance, clinical test development, and vaccine research.We hypothesize that engagement with individuals whom directly experience and/or are impacted by the increasing use of SARS-Cov-2 genetic technology, including COVID-19 Pandemic Response Biobank contributors and interdisciplinary expert teams will help identify ethical and social issues in adopting and implementing emerging technology.

    

2. A Study to Analyze Algorithms for Evaluating Early Detection of SARS-CoV/COVID-19 Infection in Critical Service Employees

   Rochester, Minn.

   The purpose of this study is to develop algorithms that will enable earlier identification and testing triggers for COVID-19 in otherwise asymptomatic patients, and to identify baseline characteristics from patients that ultimately test positive for COVID-19 that may predict clinical trajectory during the evolution of disease.

    

3. A Study to Evaluate The Role of Mucosal Microbiome in Recurrence of Clostridium Difficile Infection

   Rochester, Minn.

   The microbiome within the gut lumen has been found in prior studies to differ in individuals with C. difficile infection (CDI) in comparison to those without diarrhea. The microbiome associated with the mucosal surface on the colon has been noted to differ from that of the lumen in other clinical scenarios, although this has not been studied in depth in patients with CDI. The goal of this research is to characterize the mucosal microbiome in patients with CDI after treatment to characterize this microbiome and determine the effect on recurrence of CDI.

4. A Study to Compare the Effectiveness and Safety of ABT-493/ABT-530 to Sofosbuvir Given Together with Declatasvir in Adults with a Chronic Hepatitis C Virus Infection

   Scottsdale/Phoenix, Ariz.

   The purpose of this study is to compare the safety and effectiveness of using ABT-493/ABT-530, to the combination of sofosbuvir and daclatasvir in treating adults with genotype 3 chronic hepatitis C virus infection.

5. An Extension of a Previous Study Evaluating the Use of SER-109 to Prevent Recurrent Clostridium Difficile Infections

   Rochester, Minn.

   The purpose of this study is to extend the previous SERES-004 study in patients who had a recurrence of clostridium difficile infection within the first 8 weeks of participation.  

6. An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection

   Scottsdale/Phoenix, Ariz.

   This protocol will seek to enroll up to 60 immunocompromised subjects diagnosed with parainfluenza infection.

   All subjects will have additional PK and Immunogenicity blood samples collected.

7. Early Fluconazole Treatment for Coccidiodomycosis Pneumonia

   Scottsdale/Phoenix, Ariz.

   This is a Phase IV randomized, double-blinded, placebo-controlled study in 1000 individuals aged 18 years or older, with community acquired pneumonia (CAP) who meet all eligibility criteria in endemic regions. This study is designed to provide data on the effectiveness of early antifungal treatment (Fluconazole, 400 mg/day) for coccidioidomycosis pneumonia (also referred to as Valley Fever (VF) Pneumonia or acute onset valley fever) vs. placebo in subjects with coccidioidomycosis pneumonia. Patients who are prescribed antibacterials by their health care provider for acute CAP will be randomized to receive either placebo or 400 mg/day of fluconazole for 42 days. The primary objective is to assess the clinical response of early empiric antifungal therapy with fluconazole through Day 22 in subjects with coccidioidomycosis pneumonia and are compliant with the study intervention.

8. A Study of Fecal Microbiota Transplantation for Recurrent Clostridium Difficile Infection on Vancomycin Resistant Enterococci Status of Patients

   Rochester, Minn.

   The purpose of this study is to evaluate if Vancomycin Resistant Enterococci (VRE) can be eradicated in patients with Clostridium Difficile infection (CDI) through treatment with Fecal Microbiota Transplantation (FMT) when FMT is being done to treat recurrent CDI rather than VRE.

    

9. Long Term Prognosis of Neuroinvasive West Nile Infection

   Rochester, Minn.

   The purpose of this study is to assess short and long term outcomes and factors related to poor prognosis in patients with neuroinvasive West Nile disease

10. A Study to Evaluate the QuantiFERON-TB Gold-Plus Test for Blood Detection of Tuberculosis without Symptoms

    Rochester, Minn.

    The purpose of this study is to evaluate the new QFT-Plus assay compared to the QFT-Gold assay and the tuberculin skin test results (as available) for the detection of tuberculosis without symptoms in high-risk patients.